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a b s t r a c t
In the treatment of multiple sclerosis (MS), interferon beta (IFNb) applies. It rarely can lead to
acute liver failure (ALF).
A 42-year-old female with MS was admitted to the Department because of jaundice,
general weakness, drowsiness and nausea. Four weeks earlier, she had started therapy with
IFNb-1a. Liver tests made prior to initiation of IFNb-1a were normal but on admission to the
Department exceed several times the upper limit. ALF was recognized and IFNb-1a was
immediately stopped. In the fourth day of hospitalization, symptoms of hepatic encepha-
lopathy have progressed. The patient was transferred to the Department of Transplantation,
where hepatic coma developed and three days later the orthotopic liver transplantation was
performed. In histopathological picture of the removed liver extensive necrosis and ﬁbrosis
dominated. Immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil
and tapering prednisone. Within ﬁve years after surgery, there was no recurrence of
symptoms of MS and the transplanted organ is functioning properly.
ALF is a rare complication of IFNb therapy but it can occur. The appearance of symptoms
suggestive of liver injury should prompt extension of diagnosis and, if necessary, discon-
tinuation of therapy.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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In the treatment of relapsing remitting multiple sclerosis (MS),
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least by 30%. Therapy with IFNb is associated with numerous
side effects, among which the most common are, also known
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observations have also identiﬁed the potential hepatotoxicity.
Approximately in 23% and 67% of patients treated respectively
with IFNb-1a at a dose of 30 mg intramuscularly (im) once a
week or at a dose of 44 mg subcutaneously three times weekly,
an increase in the activity of liver enzymes was observed;
mostly of mild and transient character [1]. However, IFNb can
lead to acute liver failure. The paper presents the history of
a patient requiring liver transplantation due to this reason.
2. Case report
A 42-year-old, Caucasian woman was admitted to the
Department on June 16th 2010 because of jaundice, general
weakness, drowsiness, nausea and vomiting. Four weeks
earlier, she had started therapy with interferon b-1a (Avonex®Fig. 1 – Brain MRI performed in April 2010 (before immunosuppre
occiput horn of the left lateral cerebral ventricle: (A) axial T2-we
image after iv contrast; (D) lesion of increased signal in the corpBiogen Idec Limited, Berkshire, United Kingdom) at a dose of
30 mg im once a week, because of multiple sclerosis. She was
diagnosed with clinical isolated syndrome (CIS) in December
2008 because of the incident of amblyopia quadrant of the left
eye. At that time, magnetic resonance imaging of the brain
(MRI) was made and did not show any lesions. She was treated
with methylprednisolone at a dose of 1.0 g intravenously (iv)
for three days with a full improvement. The second time the
symptoms of retrobulbar optic neuritis with the accompa-
nying general weakness appeared in April 2010. Again
methylprednisolone was applied and then prednisone in
decreasing doses, with a partial recovery. Brain MRI revealed
demyelinating lesions in the occiput horn of the left lateral
cerebral ventricle 17 mm  12 mm, numerous lesions dissem-
inated in space and thickening of the optic nerve in intracanal
section (Fig. 1). MS was diagnosed according to the Mc Donald
criteria revised by Polman et al. [2]. The patient was qualiﬁed tossive therapy). Lesion of increased signal with edema in the
ighted image; (B) axial FLAIR image; (C) axial, T1-weighted
us callosum, axial PD image.
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more, her medical history has shown that she applied oral
contraceptives for over 10 years and for three sumatriptan 1–2
times a month due to migraine. She did not consume alcohol,
mushrooms, herbs, dietary supplements and did not take any
other drugs. She denied any liver disease. Liver tests made
immediately prior to initiation of interferon b-1a were within
normal limits: alanine aminotransferase activity was 29 U/L
(normal range < 33), aspartate aminotransferase 34 U/L (nor-
mal range < 34), g-glutamyltransferase 19 U/L (normal range
5–36), bilirubin 8.55 mmol/L (normal range < 17.1). On admis-
sion to the Department the values of liver tests exceed several
times the upper limit (Table 1). Acute liver failure was
recognized. The administration of interferon b-1a was
immediately stopped and treatment with methylpredniso-
lone (1.0 g iv daily), ornithini aspartas (15 g iv/day), rifaximin
(1.2 g orally/day), supplementation of vitamin K (10 mg iv/
day) and prophylactic antibiotics administration (ceftriaxone
1.0 g iv/day) was initiated. Viral hepatitis A, B and C, infections
with cytomegalovirus, Epstein–Barr virus, herpes simplex
virus, Wilson's disease and alpha-1 antitrypsin deﬁciency
were excluded. High levels of antibodies were found against
double-stranded DNA 42.5 IU/mL (normal < 10), U1 ribonuk-
leoprotein 14.6 U/mL (normal < 5), cytoplasmic reacting with
myeloperoxidase 20.8 U/mL (normal < 7) and Symphony
1.2 U/mL (normal < 0.7) (screening test for the detection of
antinuclear antibody associated with systemic lupus erythe-
matosus and other connective tissue diseases). Levels of
immunoglobulins IgG, IgM, and IgA were within normal
limits. Ultrasonography of the abdomen showed increased
echogenicity and irregular echostructure of the liver andTable 1 – Results of selected laboratory tests from the patient's
Result/normal range One day before
admission to the
hospital (15.06.2010)
1st day of
hospitalizatio
(16.06.2010)
Hb (120–160 g/L) 134 119 
WBC (4–10  109/L) 6.24 9.1 
Platelets (140–440  109/L) 222 184 
ALT (<31 U/L) 1045 830 
AST (<31 U/L) 867 949 
B. total/dir (<17.1/<3.42 mmol/L) 301/174 282/213.6 
ALP (35–104 U/L) 137 – 
GGT (5–36 U/L) 266 – 
INR (0.81–1.1) 2.37 2.38 
Fibrynogen (1.8–3.5 g/L) – 1.30 
PT (9.4–13.5 s) – 24.4 
AT III (70–130%) – 18.7 
TP (64–83 g/L) 51.83 
Al (40.2–47.6 g/L) – – 
Cholesterol (<5.17 mmol/L) 4.24 – 
Ammonia (31–123 mg/dL) – 98 
Creatinine (44–80 mmol/L) 80 36.24 
Urea (2.1–7.1 mmol/L) 2.68 2.1 
Glucose fasting (3.8–5.8 mmol/L) – 6.55 
Hb, hemoglobin; WBC, white blood cell count; ALT, alanine aminotra
bilirubin; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase
antithrombin III; TP, total protein; Al, albumin; OLT, orthotopic liver trana mild ascites. Magnetic resonance imaging revealed diffuse
hepatic signal abnormality suggestive of acute inﬂammatory
hepatic changes. The gastroscopy revealed no features of
portal hypertension. In the fourth day of hospitalization,
despite treatment symptoms of hepatic encephalopathy
II ! III8 have progressed. The patient was transferred to the
Department of Transplantation, where hepatic coma devel-
oped and three days later the orthotopic liver transplantation
was performed. The removed liver was very small:
15.5 cm  13 cm  7 cm. The histopathological ﬁndings of
the removed liver revealed extensive ﬁelds of fresh necrosis
and areas of postnecrotic ﬁbrosis. Focally the liver tissue
showed areas of massive necrosis and ﬁbrosis and in the
remaining areas one can observe portal–portal and portal–
central bridging hepatic necrosis. Diffuse hepatic ﬁbrosis
caused replacement of normal liver lobular architecture by
parenchymal nodules. Our attention was drawn by a promi-
nent loss of interlobular ductules (ductopenia) in numerous
portal areas. There were also moderate mononuclear cells
inﬂammatory inﬁltrates within portal tracts, features of
ductular reaction with increased number of ductular proﬁles
within the areas of ﬁbrosis and prominent bile stasis. All
of those above described histopathological ﬁndings may
correspond to extensive, drug induced hepatic injury. The
postoperative complications were not observed. The patient
in good general condition was discharged from hospital two
weeks after liver transplantation. Immunosuppressive ther-
apy consisted of tacrolimus (Prograf® Astellas Pharma,
Berkshire, Ireland), mycophenolate mofetil (CellCept® Roche
Pharma, Grenzach Wyhlen, Germany) and tapering predni-
sone. Within ﬁve years after surgery, there was no recurrence treatment period.
n
2nd day of
hospitalization
(17.06.2010)
3rd day of
hospitalization
(18.06.2010)
4th day of
hospitalization
(19.06.2010)
One
week
after OLT
116 126 128 110
8.3 21.7 18.9 8.5
178 211 204 764
634 575 471 36
545 399 191 27
286.4 319.4 – 20.7
110 – – 100
165 – – 103
2.38 2.15 1.73 0.96
– 1.59 – 3.44
– 22.6 20.3 11.2
– – – –
49.6 67
27.8 – – 39
3.0 – – –
– 108 – –
30.05 22.98 32.7 53.9
– 3.45 4.35 7.14
11.54 6.99 7.04 4.27
nsferase; AST, aspartate aminotransferase; B. total/dir, total/direct
; INR, international normalized ratio; PT, protrombin time; AT III,
splantation.
Fig. 2 – Brain MRI performed in October 2012 (after
immunosuppressive therapy). (E) Partial remission of
lesion showed on Fig. 1A–C, axial FLAIR image.
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organ is functioning properly.
3. Discussion
Acute liver failure (ALF) is a dramatic but rare clinical
syndrome marked by a sudden loss of hepatic function in
previously normal individuals. It usually presents with
coagulopathy and any degree of hepatic encephalopathy,
the length of illness being considered anything ≤26 weeks.
Currently in developed countries, the most common cause is
acetaminophen overdose and idiosyncratic drug reaction [3].
The mechanism of IFN beta induced hepatotoxicity in MS
patients is unknown. IFNb can probably cause liver injury as a
result of an idiosyncratic reaction, a hypersensitivity reaction
or it may indeed induce autoimmune reaction in an already
susceptible host [4–6]. It is likely that the liver injury in our
patient was due to an idiosyncratic reaction because it
typically occurs within weeks of initial exposure to IFNb and
may continue to evolve even after drug withdrawal. Short
duration and low cumulative dose of IFNb (120 mg) taken by the
patient by the time of ALF and increase of symptoms despite
discontinuation of treatment may conﬁrm this hypothesis. In
addition, lack of response to steroids and liver histology
support the direct nature of drug induced liver injury.
Although numerous autoantibodies were detected in the
patient, involvement of the autoimmune mechanism in the
development of acute liver failure is doubtful, because in
approximately 45% of patients with MS, presence of auto-
antibodies is concluded before the start of treatment with
interferon beta, mainly antinuclear and anti-smooth muscle
antibodies, whose titer at the time of treatment ﬂuctuates. Ithas been proved that their mere presence and variable name
during treatment with interferon beta does not justify a
diagnosis of autoimmune diseases [7]. However, reports of
the development of the autoimmune ALF after application
of interferon beta were described [5,6].
In the patient's laboratory studies dominated hyperbilir-
ubinemia and high activity of aminotransferases, reﬂecting
mainly the damaged hepatocytes. The patient ingested for a
long time oral contraceptives and sumatriptan but their share
in the development of ALF seems unlikely. Contraceptives
cause mainly the increase of cholestasis parameters whereas
sumatriptan rarely causes small changes in aminotrans-
ferases.
Most of the IFNb induced liver damage cases are revealed
during the ﬁrst six, at the latest twelve months of use, so it
is recommended to determine the level of bilirubin and
aminotransferase levels every month during the ﬁrst three
months of treatment and then every three months, and always
in the case of the onset of symptoms suggestive of liver injury
[8,9]. This procedure allows to detect early damage to the dose-
dependent IFNb. However, it does not matter in the prevention
of idiosyncretic liver damages because, as in the present case,
they are virtually impossible to predict. Some risk factors,
linked to liver damage caused by IFNb and expressed in
elevated liver test results, are known: male sex, high-
frequency dose, ﬁrst 6–15 months of treatment [1,9–11].
Female sex is risk factor for acute liver failure [10].
The patient within 5 years after liver transplantation
showed no neurological symptoms indicating both the
progress of MS and side effects of immunosuppressive drugs.
It may emphasize beneﬁcial effect of immunosuppressive
therapy on the course of MS. It can be explained by the
observation made in animal model. Tacrolimus used in mice
markedly protects against demyelination and axonal loss [12].
It is very important for both patient and doctor to maintain
the remission as long as possible. Currently the guidelines for
management of MS relapse in patients after liver transplanta-
tion are not available. The immunomodulatory drugs for
multiple sclerosis are associated with a variety of adverse drug
reactions, including liver and cardiac injury, infections [13].
Readministering of IFNb is strictly contraindicated. Also, the
use of ﬁngolimod (an antagonist of normal endogenous
sphingosine-1-phosphate) is contraindicated due to the
increased risk of opportunistic infections in patients receiving
immunosuppressive drugs [13]. Likewise natalizumab (mono-
clonal antibody which prevents migration of lymphocytes
across the blood brain barrier by blocking alpha-4-integrin
adhesion molecules) may increase the risk of common or
opportunistic infections. Signiﬁcant liver injury due to
natalizumab is possible but rare [14]. Thus, choice of the
treatment method depends on the experience of the doctor,
relation of risks to losses and co-existing diseases.
The differential diagnosis of multiple sclerosis usually
includes diseases which cause more than one neurological
symptom and extend in a chronic or recurrent way and in the
course of which MRI hyperintense there are variations in the
sequences T2/PD. For patients diagnosed with MS and
abnormal liver function primarily autoimmune liver diseases
(autoimmune hepatitis, primary biliary cirrhosis), drug-in-
duced liver injury and Wilson's disease (WD) should be taken
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 4 5 1 – 4 5 5 455into consideration. In the ﬁrst case, the diagnosis of liver
disease may be ultimately decided as the result of liver biopsy
in the second one through physical examination. WD should
be suspected in patients with neurological signs not typical for
MS and behavioral problems. Copper metabolism test (serum
ceruloplasmin level, copper serum concentration, 24-h urinary
copper excretion) and genetic analysis of mutation in the allele
of the ATP7B gene conﬁrm the diagnosis of WD. Kayser–
Fleischer rings are not always present. Co-existence of these
diseases seems to be coincidental. However, there could be
potential inﬂuence of one disease upon another [15,16].
4. Conclusion
Liver damages caused by interferon beta use, are mostly mild,
asymptomatic and transient and monitoring the level of
bilirubin and aminotransferase levels allows for their early
detection. ALF is a very rare complication of IFNb therapy but
can occur. The appearance of symptoms suggestive of liver
injury should prompt extension of diagnosis and, if necessary,
discontinuation of therapy.
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